| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Pharmaceutical Technology and Biochemistry, Technical University of Gdansk, 80-952 Gdansk, Poland
To determine whether the toxic effects and changes in many cell functions caused by antitumor 1-nitroacridines are related to their enzymatically mediated covalent interstrand DNA cross-linking (J. Konopa, J. W. Pawlak, and K. Pawlak. Chem.-Biol. Interact., 43: 175197, 1983), the cross-linking potency of the derivatives with structural modifications in position 9 of the acridine nucleus was estimated as their in vitro threshold concentrations (0.3 to 4.5 µM), beyond which the first interstrand DNA cross-links could be detected in DNA of cultured HeLa S3 cells with a polyethylene glycol 6000-Dextran T500 assay. Statistically significant (p < 0.05) correlations exist between the cross-linking potency of 1-nitroacridines and their in vivo antitumor activity and toxicity against mice with Sarcoma 180 tumors in solid form (3 to 1065 µmol/kg of body weight), as well as their in vitro cytotoxicity against cultured HeLa or HeLa S3 cells (0.0005 to 7.2 µM), indicating that the interstrand DNA cross-linking potency might be one of primary determinants of in vivo and in vitro biological activity of 1-nitroacridine antineoplastic drugs. Susceptibility of the parent agents to reduction does not appear to be a rate-limiting factor of DNA cross-linking potency of 1-nitroacridines and their metabolic transformations (J. W. Pawlak, and J. Konopa. Biochem. Pharmacol., 28: 33913402, 1979), because no significant differences were observed among the agents with respect to their polarographic half-wave potentials estimated under anaerobic conditions.
1 Supported by Grant PR-6/1704 from the Polish National Cancer Program, continued by Jerzy Konopa, Ph.D., and associates at the Department of Pharmaceutical Technology and Biochemistry, Technical University of Gdansk, Majakowskiego 11/12, 80-952 Gdansk 6, Poland. A preliminary communication of part of this work was presented at the 17th Meeting of the Polish Biochemical Society, September 11 to 13, 1980, Warsaw, Poland (Abstract), and at the 13th International Cancer Congress, September 8 to 15, 1982, Seattle, WA. This is Paper 4 in a series on "The Mode of Action of Cytotoxic and Antitumor 1-Nitroacridines."
2 Recipient of Yale Grants 703A-41-55257 and -6992 at the Department of Pharmacology of Yale University School of Medicine (1981 to 1983), from the funds generously donated by Mr. and Mrs. J. Seward Johnson, The J. Seward Johnson Charitable Trust Foundation 1961 and 1963, and Johnson & Johnson, Inc.
3 Present address: Department of Pharmacy, School of Pharmacy, University of California at San Francisco, Parnassus St. and 1st Ave., San Francisco, CA 94143.
4 To whom requests for reprints should be addressed, at Bruce Lyon Memorial Research Laboratory, Children's Hospital Medical Center of Northern California, 51st and Grove St., Oakland, CA 94609.
Received 10/20/82. Accepted 6/19/84.
This article has been cited by other articles:
![]() |
S. M. Tsai, M. E. Farkas, C. J. Chou, J. M. Gottesfeld, and P. B. Dervan Unanticipated differences between {alpha}- and {gamma}-diaminobutyric acid-linked hairpin polyamide-alkylator conjugates Nucleic Acids Res., January 12, 2007; 35(1): 307 - 316. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-D. Wang, J. Dziegielewski, N. R. Wurtz, B. Dziegielewska, P. B. Dervan, and T. A. Beerman DNA crosslinking and biological activity of a hairpin polyamide-chlorambucil conjugate Nucleic Acids Res., February 15, 2003; 31(4): 1208 - 1215. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |